文献速递炎症性肠病

欧洲人群基础起始队列中克罗恩病诊断后5年内的自然病程:Epi-IBD研究

Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study.
PubMed 文献 · Gut · 2018-01-23

488例CD患者中,22%接受手术,36%因CD住院,14%的非狭窄非穿透型进展为狭窄和/或穿透型;免疫调节剂治疗降低手术风险(HR 0.4,95%CI 0.2-0.6)和住院风险(HR 0.3,95%CI 0.2-0.5)。西欧与东欧5年结局相当,治疗策略差异未影响病程。

要点

  • 488例CD患者诊断后5年内,22%接受手术,36%因CD住院。
  • 14%的非狭窄非穿透型患者进展为狭窄和/或穿透型。
  • 免疫调节剂治疗降低手术风险(HR 0.4,95%CI 0.2-0.6)和住院风险(HR 0.3,95%CI 0.2-0.5)。

核心结论

  • 尽管西欧患者早期且频繁接受免疫调节剂和生物制剂治疗,该队列5年结局包括手术和表型进展在西欧与东欧间相当。
  • 西欧与东欧中心治疗策略的差异未影响疾病病程。
  • 免疫调节剂治疗降低了手术和住院风险。

研究设计与样本

  • 患者自诊断时起前瞻性随访,收集临床数据、人口学、疾病活动度、药物治疗、手术、肿瘤和死亡资料。
  • 采用Cox回归分析结局与多个协变量的关联。
  • 共纳入488例克罗恩病(CD)患者。

主要发现

  • 随访期间107例(22%)患者接受手术,176例(36%)患者因CD住院。
  • 49例(14%)诊断为非狭窄非穿透型疾病的患者进展为狭窄和/或穿透型疾病。
  • 上述发生率在西欧与东欧患者间无差异。
  • 西欧较东欧更多患者接受生物制剂治疗(33% vs 14%)和免疫调节剂治疗(66% vs 54%),P<0.01。
  • 东欧较西欧更多患者接受5-氨基水杨酸类治疗(90% vs 56%),P<0.05。

关键数值与推荐

  • 免疫调节剂治疗降低手术风险:HR 0.4(95%CI 0.2-0.6)。
  • 免疫调节剂治疗降低住院风险:HR 0.3(95%CI 0.2-0.5)。
  • 西欧生物制剂使用率33% vs 东欧14%,P<0.01。
  • 西欧免疫调节剂使用率66% vs 东欧54%,P<0.01。
  • 东欧5-氨基水杨酸类使用率90% vs 西欧56%,P<0.05。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Epi-IBD cohort is a prospective population-based inception cohort of unselected patients with inflammatory bowel disease from 29 European centres covering a background population of almost 10 million people. The aim of this study was to assess the 5-year outcome and disease course of patients with Crohn's disease (CD). DESIGN: Patients were followed up prospectively from the time of diagnosis, including collection of their clinical data, demographics, disease activity, medical therapy, surgery, cancers and deaths. Associations between outcomes and multiple covariates were analysed by Cox regression analysis. RESULTS: In total, 488 patients were included in the study. During follow-up, 107 (22%) patients received surgery, while 176 (36%) patients were hospitalised because of CD. A total of 49 (14%) patients diagnosed with non-stricturing, non-penetrating disease progressed to either stricturing and/or penetrating disease. These rates did not differ between patients from Western and Eastern Europe. However, significant geographic differences were noted regarding treatment: more patients in Western Europe received biological therapy (33%) and immunomodulators (66%) than did those in Eastern Europe (14% and 54%, respectively, P<0.01), while more Eastern European patients received 5-aminosalicylates (90% vs 56%, P<0.05). Treatment with immunomodulators reduced the risk of surgery (HR: 0.4, 95% CI 0.2 to 0.6) and hospitalisation (HR: 0.3, 95% CI 0.2 to 0.5). CONCLUSION: Despite patients being treated early and frequently with immunomodulators and biological therapy in Western Europe, 5-year outcomes including surgery and phenotype progression in this cohort were comparable across Western and Eastern Europe. Differences in treatment strategies between Western and Eastern European centres did not affect the disease course. Treatment with immunomodulators reduced the risk of surgery and hospitalisation.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Burisch J, Kiudelis G, Kupcinskas L, et al. Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut. 2018. PMID: 29363534. doi:10.1136/gutjnl-2017-315568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。